Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With Nab-Paclitaxel and Carboplatin in Advanced Non-Small Cell Lung Cancer
Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.01256
Full Text
Open PDFAbstract
Available in full text
Date
November 26, 2019
Authors
Publisher
Frontiers Media SA